Monte Rosa Therapeutics, Inc. (GLUE) stock — the fundamentals (P/E, market cap, valuation) and every material event, decoded in plain English.
Key numbers for Monte Rosa Therapeutics, Inc. (GLUE): P/E ratio, market cap, profit margins, returns, and whether the stock looks cheap or expensive versus its own 5-year range.
AllSight quality score: 33/100 — a percentile rank of Monte Rosa Therapeutics, Inc.’s fundamentals against Manufacturing peers, weakest on growth. A quality ranking, not a price prediction.
| Market cap | $960.6M |
| P / S | 33.4× |
| EV / EBITDA | -5.0× |
| Gross margin | 100.0% |
| Operating margin | -633.0% |
| Net margin | -560.9% |
| Return on equity | -33.1% |
| ROIC | -45.0% |
| Revenue growth | -83.9% |
| Debt / equity | 0.0× |
| Dividend yield | 0.0% |
Is Monte Rosa Therapeutics, Inc. overvalued? P/S looks fair vs its 5-year range; P/B looks fair vs its 5-year range.
Independent of the events above — derived from Monte Rosa Therapeutics, Inc.’s own financial statements and shown as context, never as advice.
About AllSight · Editorial standards & method · Contact